The retirement of a specific FDA official is seen as a bullish catalyst, with the speaker suggesting 'this allows Replimune to get approved.'

The host is bullish, stating 'I still think it's a buy' and expressing that he was considering purchasing the stock again.

Bullish view based on a valuation argument, as the stock is 'trading near cash.' It's called a 'pretty good buy' and a 'good speculative long' because the market is assigning little value to its drug pipeline, which 'seems to work'.

Speaker remains bullish but sold half their position to take profits, suggesting a strategy of locking in gains while maintaining some exposure.

The speaker's third biggest long position, viewed as a high-risk, high-reward investment dependent on a 50/50 FDA approval decision. The speaker is considering selling half to de-risk after a recent double.

Viewed as a short-term, speculative trade. The speaker bought a small amount due to the stock being oversold and its large cash reserves, expecting a small bounce despite being critical of its clinical trial strategy.